BiotechTube

APR-246

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions

Acute Myeloid Leukemia or Myelodysplastic Syndromes

Trial Timeline

Sep 16, 2019 → Jan 14, 2022

NCT ID
NCT03931291

About APR-246

APR-246 is a phase 2 stage product being developed by Aprea Therapeutics for Acute Myeloid Leukemia or Myelodysplastic Syndromes. The current trial status is completed. This product is registered under clinical trial identifier NCT03931291. Target conditions include Acute Myeloid Leukemia or Myelodysplastic Syndromes.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT03931291Phase 2Completed
NCT00900614Phase 1Completed

Competing Products

20 competing products in Acute Myeloid Leukemia or Myelodysplastic Syndromes

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
SPT-07A injectionSinopharmPhase 3
76
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77

Other Products from Aprea Therapeutics

APR-246 + azacitidine + AzacitidinePhase 3
69
APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Phase 2
44
APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Phase 1/2
33
APR-246 (eprenetapopt) + Acalabrutinib in CLL + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL + APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RTPhase 1/2
33
APR-246 + AzacitidinePhase 1/2
33